Cyclo Therapeutics, Inc. (CYTH)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Cyclo Therapeutics, Inc. (CYTH)

Company Performance

Current Price

as of Oct 18, 2024

$0.77

P/E Ratio

N/A

Market Cap

$22.21M

Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Metrics

Overview

HQGainesville, FL
SectorHealth Technology
IndustryBiotechnology
TickerCYTH
Price$0.774-1.39%

Trading Information

Market Cap$22.21M
Float57.90%
Average Daily Volume (1m)33,506
Average Daily Volume (3m)78,642
EPS-$0.88

Company

Revenue$1.13M
Rev Growth (1yr)5.11%
Net Income-$5.98M
Gross Margin-656.37%
EBITDA Margin-4,576.22%
EBITDA-$5.63M

EV$38.25M
EV/Revenue33.77
P/EN/A
P/S19.57
P/BN/A

Documents

Factset Street Account

Cyclo Therapeutics reports Q3 GAAP EPS ($0.29) vs year-ago ($0.50) - 10-Q ($1.44, -0.02) (2023-11-14T19:53:07Z)

Cyclo Therapeutics announces outcome from Type C Meeting with the U.S. FDA discussing Trappsol Cyclo clinical program for the treatment of Niemann-Pick Disease Type C1 ($1.37, 0.00) (2023-12-18T14:18:42Z)

Factset

Factset Business Description